

Seagen Inc (SGEN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/S1D58F31C34EN.html>

Date: February 2021

Pages: 59

Price: US\$ 125.00 (Single User License)

ID: S1D58F31C34EN

Abstracts

Seagen Inc (SGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Seagen Inc (Seagen), formerly Seattle Genetics Inc, is a biotechnology company that discovers, develops and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs) including Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma, T-cell lymphomas, and CD30-expressing lymphomas; and Padcev (enfortumab vedotin-ejfv) to treat metastatic urothelial cancers. The company's pipeline consists of novel therapies that for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology that targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.

Seagen Inc Key Recent Developments

Feb 24,2021: Seagen to Present at the Cowen 41st Annual Healthcare Conference

Feb 11,2021: Seagen Reports Fourth Quarter and Full Year 2020 Financial Results

Nov 09,2020: Seagen **Highlights** immuno-oncology data from broad portfolio during SITC Virtual Annual Meeting 2020

Oct 29,2020: Seagen reports third quarter 2020 financial results

Oct 08,2020: Seattle Genetics announces corporate name change to Seagen

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents

List of Tables

List of Figures

SECTION 1 - ABOUT THE COMPANY

Seagen Inc - Key Facts

Seagen Inc - Key Employees

Seagen Inc - Key Employee Biographies

Seagen Inc - Major Products and Services

Seagen Inc - History

Seagen Inc - Company Statement

Seagen Inc - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

Seagen Inc - Business Description

Business Segment: Collaboration and License Agreement Revenue

Performance

Business Segment: Net Product Sales

Performance

Business Segment: Royalty Revenues

Performance

R&D Overview

Seagen Inc - Corporate Strategy

Seagen Inc - SWOT Analysis

SWOT Analysis - Overview

Seagen Inc - Strengths

Seagen Inc - Weaknesses

Seagen Inc - Opportunities

Seagen Inc - Threats

Seagen Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Seagen Inc (SGEN) - Financial and Strategic SWOT Analysis Review

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Seagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Seagen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Seagen Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 24, 2021: Seagen to Present at the Cowen 41st Annual Healthcare Conference

Feb 11, 2021: Seagen Reports Fourth Quarter and Full Year 2020 Financial Results

Nov 09, 2020: Seagen highlights immuno-oncology data from broad portfolio during SITC Virtual Annual Meeting 2020

Oct 29, 2020: Seagen reports third quarter 2020 financial results

Oct 08, 2020: Seattle Genetics announces corporate name change to Seagen

Aug 27, 2020: Seattle Genetics highlights data from broad oncology portfolio during ESMO Virtual Congress 2020

Aug 18, 2020: Seattle Genetics appoints Ted W. Love, M.D., to Board of Directors

Jul 30, 2020: Seattle Genetics reports second quarter 2020 financial results

May 13, 2020: Seattle Genetics highlights data from expanding oncology portfolio during virtual scientific program of the 2020 ASCO annual meeting

Apr 30, 2020: Seattle Genetics reports first quarter 2020 financial results

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Seagen Inc, Key Facts
Seagen Inc, Key Employees
Seagen Inc, Key Employee Biographies
Seagen Inc, Major Products and Services
Seagen Inc, History
Seagen Inc, Subsidiaries
Seagen Inc, Key Competitors
Seagen Inc, Ratios based on current share price
Seagen Inc, Annual Ratios
Seagen Inc, Annual Ratios (Cont...1)
Seagen Inc, Interim Ratios
Seagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Seagen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Seagen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Seagen Inc, Performance Chart (2016 - 2020)

Seagen Inc, Ratio Charts

Seagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Seagen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Xencor Inc

Teva Pharmaceuticals USA Inc

Spectrum Pharmaceuticals Inc

Sanofi AB

Pfizer AG

Novartis AG

ImmunoGen Inc

Dare Bioscience Inc

Cellectar Biosciences Inc

Celgene Corp

Bristol-Myers Squibb Co

Amgen Inc

I would like to order

Product name: Seagen Inc (SGEN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/S1D58F31C34EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S1D58F31C34EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970